ClearNote Health will be attending the 14th World CB & CDx Boston Summit. Find us at booth 35 and learn more about the advantages of the Virtuoso Epigenomics Platform, our liquid based monitoring tools and the power of longitudinal analysis in your translational research program.
Virtuoso represents a paradigm shift in drug development, offering non-invasive testing, longitudinal research capabilities, and individualized patient epigenomics to reveal critical biological changes in plasma. By leveraging these capabilities, the Virtuoso Platform accelerates drug development and advances precision medicine.
Plus, if you are attending the event, make sure not to miss the talk from our collaborator, Novartis:
Presenter: Connie Wong, Director – Global Biomarker Diagnostics
Company: Novartis AG
Title: Leveraging Novel Liquid Biopsy Technology to Accelerate Translational Research: Circulating Free DNA 5-hydroxymethylcytosine Profiling in Patients with Pancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTA-TATE Time: 2:50 pm, Day Two Track B
Details:
– The use of circulating free DNA and its epigenomic status to infer tumor gene expression
– Insights into the mechanism of action of radioligand therapy, a targeted radioactive treatment for cancer
– Leveraging epigenomic status in blood samples to identify predictive biomarker candidates
